J.P. Morgan analyst Anupam Rama has maintained their bullish stance on NBIX stock, giving a Buy rating on August 1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anupam Rama has given his Buy rating due to a combination of factors including the promising outlook for Neurocrine’s key products and the company’s strategic positioning. The recent launch of Crenessity has shown strong performance, with expectations for continued growth as estimates are adjusted upward. This product is anticipated to achieve blockbuster status, driven by its increasing adoption in the US market.
Additionally, Ingrezza remains a significant contributor to Neurocrine’s potential, despite facing some pricing pressures. The company is proactively managing these challenges by focusing on expanding its market share and patient base. The long-term prospects for both Crenessity and Ingrezza, along with an underappreciated late-stage pipeline, underscore the positive outlook for Neurocrine’s stock.
In another report released on August 1, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $145.00 price target.